Trial Profile
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms ANITSCHKOW
- Sponsors Amgen
- 08 Apr 2020 Results (n=32) assessing gene expression profile of circulating monocytes of healthy individuals and CVD patients, both with elevated Lp(a) in two studies (AKCEA-APO(a)-LRx study (NCT03070782) and the ANITSCHKOW study (NCT02729025)), published in the European Heart Journal.
- 18 Dec 2018 Primary endpoint (Effect of Repatha (Evolocumab) on Lp(a), as measured by percent change from baseline at week 16 in target-to-background ratio of an index vessel by FDG-PET/CT in subjects with baseline Lp(a)50mg/dL and Low-density lipoprotein-cholesterol100mg/dL) has not been met as per results published in the European Heart Journal
- 18 Dec 2018 Results published in the European Heart Journal